Ketamine activates psychosis and alters limbic blood flow in schizophrenia

A. C. Lahti, H. H. Holcomb, D. R. Medoff, C. A. Tamminga

Research output: Contribution to journalArticle

326 Citations (Scopus)

Abstract

The non-competitive NMDA antagonist ketamine, given to schizophrenic individuals in subanesthetic doses, produced a short-lived, discrete activation of their psychotic symptoms, which had striking similarities to symptoms of their usual psychotic episodes. To further study this psychotomimetic property of ketamine, we administered 0.3 mg kg-1 of the drug to schizophrenic individuals during a [15O] water cerebral blood flow study. Regional cerebral blood flow (rCBF) was measured using H215O and positron emission tomography (PET) before and after ketamine administration to identify regions of flow change. rCBF was increased in anterior cingulate cortex and was reduced in the hippocampus and primary visual cortex (lingual and fusiform gyri). These data encourage further consideration of altered glutamatergic transmission in schizophrenic and PCP-induced psychoses.

Original languageEnglish (US)
Pages (from-to)869-872
Number of pages4
JournalNeuroReport
Volume6
Issue number6
StatePublished - 1995

Fingerprint

Cerebrovascular Circulation
Ketamine
Psychotic Disorders
Schizophrenia
Regional Blood Flow
Occipital Lobe
Gyrus Cinguli
Visual Cortex
N-Methylaspartate
Temporal Lobe
Positron-Emission Tomography
Hippocampus
Water
Pharmaceutical Preparations

Keywords

  • Cerebral blood flow
  • Cingulate
  • Glutamate
  • Hippocampus
  • Ketamine
  • Psychosis
  • Schizophrenia

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Lahti, A. C., Holcomb, H. H., Medoff, D. R., & Tamminga, C. A. (1995). Ketamine activates psychosis and alters limbic blood flow in schizophrenia. NeuroReport, 6(6), 869-872.

Ketamine activates psychosis and alters limbic blood flow in schizophrenia. / Lahti, A. C.; Holcomb, H. H.; Medoff, D. R.; Tamminga, C. A.

In: NeuroReport, Vol. 6, No. 6, 1995, p. 869-872.

Research output: Contribution to journalArticle

Lahti, AC, Holcomb, HH, Medoff, DR & Tamminga, CA 1995, 'Ketamine activates psychosis and alters limbic blood flow in schizophrenia', NeuroReport, vol. 6, no. 6, pp. 869-872.
Lahti, A. C. ; Holcomb, H. H. ; Medoff, D. R. ; Tamminga, C. A. / Ketamine activates psychosis and alters limbic blood flow in schizophrenia. In: NeuroReport. 1995 ; Vol. 6, No. 6. pp. 869-872.
@article{b154c7b1f85748deb946e14f3f0fb356,
title = "Ketamine activates psychosis and alters limbic blood flow in schizophrenia",
abstract = "The non-competitive NMDA antagonist ketamine, given to schizophrenic individuals in subanesthetic doses, produced a short-lived, discrete activation of their psychotic symptoms, which had striking similarities to symptoms of their usual psychotic episodes. To further study this psychotomimetic property of ketamine, we administered 0.3 mg kg-1 of the drug to schizophrenic individuals during a [15O] water cerebral blood flow study. Regional cerebral blood flow (rCBF) was measured using H215O and positron emission tomography (PET) before and after ketamine administration to identify regions of flow change. rCBF was increased in anterior cingulate cortex and was reduced in the hippocampus and primary visual cortex (lingual and fusiform gyri). These data encourage further consideration of altered glutamatergic transmission in schizophrenic and PCP-induced psychoses.",
keywords = "Cerebral blood flow, Cingulate, Glutamate, Hippocampus, Ketamine, Psychosis, Schizophrenia",
author = "Lahti, {A. C.} and Holcomb, {H. H.} and Medoff, {D. R.} and Tamminga, {C. A.}",
year = "1995",
language = "English (US)",
volume = "6",
pages = "869--872",
journal = "NeuroReport",
issn = "0959-4965",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Ketamine activates psychosis and alters limbic blood flow in schizophrenia

AU - Lahti, A. C.

AU - Holcomb, H. H.

AU - Medoff, D. R.

AU - Tamminga, C. A.

PY - 1995

Y1 - 1995

N2 - The non-competitive NMDA antagonist ketamine, given to schizophrenic individuals in subanesthetic doses, produced a short-lived, discrete activation of their psychotic symptoms, which had striking similarities to symptoms of their usual psychotic episodes. To further study this psychotomimetic property of ketamine, we administered 0.3 mg kg-1 of the drug to schizophrenic individuals during a [15O] water cerebral blood flow study. Regional cerebral blood flow (rCBF) was measured using H215O and positron emission tomography (PET) before and after ketamine administration to identify regions of flow change. rCBF was increased in anterior cingulate cortex and was reduced in the hippocampus and primary visual cortex (lingual and fusiform gyri). These data encourage further consideration of altered glutamatergic transmission in schizophrenic and PCP-induced psychoses.

AB - The non-competitive NMDA antagonist ketamine, given to schizophrenic individuals in subanesthetic doses, produced a short-lived, discrete activation of their psychotic symptoms, which had striking similarities to symptoms of their usual psychotic episodes. To further study this psychotomimetic property of ketamine, we administered 0.3 mg kg-1 of the drug to schizophrenic individuals during a [15O] water cerebral blood flow study. Regional cerebral blood flow (rCBF) was measured using H215O and positron emission tomography (PET) before and after ketamine administration to identify regions of flow change. rCBF was increased in anterior cingulate cortex and was reduced in the hippocampus and primary visual cortex (lingual and fusiform gyri). These data encourage further consideration of altered glutamatergic transmission in schizophrenic and PCP-induced psychoses.

KW - Cerebral blood flow

KW - Cingulate

KW - Glutamate

KW - Hippocampus

KW - Ketamine

KW - Psychosis

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=0028943849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028943849&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 869

EP - 872

JO - NeuroReport

JF - NeuroReport

SN - 0959-4965

IS - 6

ER -